Uncategorized

Incyte to buy blood disorder drug in possibly $2B deal

Acquiring Vega Therapeutics, an offshoot of “hub-and-spoke” biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

Read More

Published

on

Acquiring Vega Therapeutics, an offshoot of “hub-and-spoke” biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version